Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Vaxart operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vaxart's operating cash flow for the twelve months ending Sep 30, 2026 was $32.82M. For fiscal 2025 it was $7.71M. The highest annual figure on record is $7.71M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.71M | – |
| FY2024 | Dec 31, 2024 | -$44.76M | – |
| FY2023 | Dec 31, 2023 | -$70.45M | – |
| FY2022 | Dec 31, 2022 | -$94.78M | – |
| FY2021 | Dec 31, 2021 | -$59.83M | – |
| FY2020 | Dec 31, 2020 | -$23.75M | – |
| FY2019 | Dec 31, 2019 | -$13.09M | – |
| FY2018 | Dec 31, 2018 | -$14.55M | – |
| FY2016 | Jun 30, 2016 | -$14.10M | – |
| FY2015 | Jun 30, 2015 | -$9.60M | – |
| FY2014 | Jun 30, 2014 | -$3.30M | – |
| FY2013 | Jun 30, 2013 | -$13.90M | – |
| FY2012 | Jun 30, 2012 | -$15.90M | -355.8% |
| FY2009 | Dec 26, 2009 | $6.22M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $1.43M | -44.8% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $2.78M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$2.05M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $30.66M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $2.60M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$15.95M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$9.60M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$7.35M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$4.20M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$12.03M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$21.19M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$13.52M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$15.00M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$17.47M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$24.46M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$29.15M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$14.62M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$25.90M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$25.11M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$15.81M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$14.27M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$13.16M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$16.59M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$10.77M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$9.26M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$521.00K | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$3.21M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$3.79M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$4.33M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$317.00K | -104.5% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$4.65M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$5.70M | -618.4% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$5.36M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $7.10M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$10.59M | -1276.7% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $1.10M | +450.0% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$7.00M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$9.10M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $900.00K | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $200.00K | – |
See a number that looks wrong?